Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38407352)

  • 21. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
    Katayama R; Khan TM; Benes C; Lifshits E; Ebi H; Rivera VM; Shakespeare WC; Iafrate AJ; Engelman JA; Shaw AT
    Proc Natl Acad Sci U S A; 2011 May; 108(18):7535-40. PubMed ID: 21502504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
    Zheng J; Zhu Y; Sun K; Shen Q; Wang Y; Cao H; Lizaso A; Yu B; Lin J; Chen S; Zhou J; Zhou J
    Lung Cancer; 2020 Aug; 146():209-216. PubMed ID: 32563740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
    Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
    Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
    Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
    Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
    Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
    Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.
    Ma X; Zhang K; Xu J; Gao H; Yang S; Qin H; Wang H; Gao F; Liu X
    Thorac Cancer; 2023 Jul; 14(20):1980-1990. PubMed ID: 37265111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
    Horn L; Whisenant JG; Wakelee H; Reckamp KL; Qiao H; Leal TA; Du L; Hernandez J; Huang V; Blumenschein GR; Waqar SN; Patel SP; Nieva J; Oxnard GR; Sanborn RE; Shaffer T; Garg K; Holzhausen A; Harrow K; Liang C; Lim LP; Li M; Lovly CM
    J Thorac Oncol; 2019 Nov; 14(11):1901-1911. PubMed ID: 31446141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
    Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
    Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting
    Mezquita L; Swalduz A; Jovelet C; Ortiz-Cuaran S; Howarth K; Planchard D; Avrillon V; Recondo G; Marteau S; Benitez JC; De Kievit F; Plagnol V; Lacroix L; Odier L; Rouleau E; Fournel P; Caramella C; Tissot C; Adam J; Woodhouse S; Nicotra C; Auclin E; Remon J; Morris C; Green E; Massard C; Pérol M; Friboulet L; Besse B; Saintigny P
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
    Wang Y; Shen S; Hu P; Geng D; Zheng R; Li X
    Cancer Med; 2022 Dec; 11(23):4491-4500. PubMed ID: 35616090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
    Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
    J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant mutation status of
    Li J; Zhang B; Zhang Y; Xu F; Zhang Z; Shao L; Yan C; Ulivi P; Denis MG; Christopoulos P; Thomas de Montpréville V; Bernicker EH; van der Wekken AJ; Wang C; Yue D
    Transl Lung Cancer Res; 2021 Mar; 10(3):1525-1535. PubMed ID: 33889527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple
    Wei Q; Zhang Y; Wang Y; Desai A; Tan S; Huang Q; Pu X; Tian P; Li Y
    Transl Lung Cancer Res; 2023 Sep; 12(9):1935-1948. PubMed ID: 37854161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.
    Santarpia M; Daffinà MG; D'Aveni A; Marabello G; Liguori A; Giovannetti E; Karachaliou N; Gonzalez Cao M; Rosell R; Altavilla G
    Drug Des Devel Ther; 2017; 11():2047-2063. PubMed ID: 28740365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
    Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
    Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
    Tao H; Shi L; Zhou A; Li H; Gai F; Huang Z; Che N; Liu Z
    Lung Cancer; 2020 Nov; 149():154-161. PubMed ID: 33017727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.